miRNA in Patients With Thoracic, Abdominal and Intracranial Aneurysms

Vascular Aneurysm Clinical Trial

— miRNA  

Official title:

miRNA in Patients With Thoracic, Abdominal and Intracranial Aneurysms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05382611
• Other study ID #: IG144101
• Status: Completed
• Start date: May 19, 2018
• Est. completion date: December 31, 2021

Study information

• Verified date: May 2022
• Source: Na Homolce Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To assess the expression of miRNA in patients with TAA, AAA in aneurysmatic tissue and to compare this expression with the healthy tissue in the same patient. In the same cohort, to asses the presence of miRNA in plasma and to compare with the control group. Over the period of three years,to follow subjects in order to assess if the presence of certain miRNAs speeds up or slows down the progression of disease. In patients with intracranial aneurysms to detect miRNA in plasma especially in patients with familial occurrence.

Description:

MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. Acting at the post-transcriptional level, MicroRNAs have been shown to be involved in a wide range of biological processes such as cell cycle control, apoptosis and several developmental and physiological processes including stem cell differentiation, hematopoiesis, hypoxia, cardiac and skeletal muscle development. In addition to their important roles in healthy individuals, microRNAs have also been implicated in a number of diseases including a broad range of cancers, cardiovascular and heart disease. Their different expression in aortic tissue in patients with aortic abdominal aneurysm and their association with the progression of the disease were confirmed. They represent the potential target for the treatment of the disease. MiRNA act as biomarkers showing the potential risk of the presence of TAA, AAA and intracranial aneurysm, for the prediction of TAA and AAA progression and for the discovery of new treatment possibilities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. 18 years of age or older

2. Patient willing and able to sign clinical trial Informed Consent

3. Patient with AAA or TAA who require an open surgical procedure, or patient with intracranial aneurysm indicated for radiological intervention

Exclusion Criteria:

1. Patient with multiorgan failure

Related Conditions & MeSH terms

• Aneurysm
• Intracranial Aneurysm
• Vascular Aneurysm

Intervention

Diagnostic Test:
• ngs next generation sequencing
the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS

Locations

Country	Name	City	State
Czechia	Na Homolce Hospital	Prague

Sponsors (2)

Lead Sponsor	Collaborator
Na Homolce Hospital	Czech Academy of Sciences

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The comparison of miRNA in healthy and aneurysmatic tissue	miRNA will be compared in blood and in healthy and aneurysmatic tissue using ngs	2020 at end of trial